GlassScriptPhysician profile
Hilda E Rivera Quinones
NPI 1275682502
$11,468.33
in general payments reported to CMS, 2019-2025
36 companies · $1,855 in 2025
The $1,855 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $1,038 · 2021: $1,630 · 2022: $2,110 · 2023: $2,035 · 2024: $2,298 · 2025: $1,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,166 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,166.06 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,792.96 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,949.14 | 2019-2025 | Lynparza, Calquence, Tagrisso |
| Janssen Pharmaceuticals, INC | $1,306.50 | 2020-2025 | Darzalex, Imbruvica, Rybrevant |
| Merck Sharp & Dohme LLC | $902.21 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Eli Lilly Export S.A. Puerto Rico Branch | $801.13 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $676.07 | 2020-2025 | Venclexta, Epkinly |
| Amgen INC. | $449.11 | 2021-2025 | Kyprolis, Xgeva, Riabni |
| Pbg Puerto Rico LLC | $370.11 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $259.75 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $227.55 | 2022-2025 | |
| Bayer Puerto Rico INC. | $146.57 | 2024-2025 | Nubeqa, Stivarga, Vitrakvi |
| Genentech USA, INC. | $144.99 | 2020-2024 | Perjeta, Tecentriq, Kadcyla |
| Pfizer INC. | $142.03 | 2019-2024 | |
| Genzyme Corporation | $138.08 | 2020-2023 | |
| Glaxosmithkline, LLC. | $133.01 | 2021-2024 | Jemperli, Zejula |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $125.38 | 2020-2025 | Monjuvi, Jakafi, Pemazyre |
| Caris Mpi, INC. | $91.19 | 2025 | Mi Cancer Seek |
| Janssen Biotech, INC. | $84.95 | 2021 | |
| Karyopharm Therapeutics INC. | $77.35 | 2021-2023 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $75.00 | 2022-2023 | Vpriv |
| Eisai INC. | $71.22 | 2020-2023 | |
| Array Biopharma INC | $67.19 | 2023-2024 | Lorbrena, Braftovi, Mektovi |
| Celgene Corporation | $49.93 | 2019-2020 | |
| Pharmaessentia USA Corporation | $49.51 | 2025 | Besremi |
| Adc Therapeutics America, INC. | $45.42 | 2022 | |
| Verity Pharmaceuticals INC. | $42.39 | 2022-2023 | Akynzeo |
| Taiho Oncology, INC. | $36.32 | 2022 | |
| Sobi, INC | $35.54 | 2023-2024 | |
| Puma Biotechnology, INC. | $34.15 | 2019 | |
| Rigel Pharmaceuticals, INC. | $26.39 | 2020 | |
| Morphosys, US INC. | $24.53 | 2023 | Monjuvi |
| Emd Serono, INC. | $22.95 | 2024 | |
| Stemline Therapeutics INC. | $19.16 | 2025 | Orserdu |
| Seagen INC. | $19.16 | 2021 | |
| Gilead Sciences, INC. | $16.59 | 2023 | Trodelvy |
| Beigene USA, INC. | $14.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hilda Rivera Quinones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.